On October 16, 2025, Veeva Systems Inc. (NYSE: VEEV) announced an exciting collaboration with OpenEvidence, marking a significant advancement in the life sciences sector. This long-term partnership aims to develop and market "Open Vista," an innovative initiative designed to leverage artificial intelligence (AI) to enhance patient access to clinical trials, expedite drug discovery, and improve the understanding and adoption of existing therapies.

1. Bridging the Gap in Clinical Trials

The partnership between Veeva and OpenEvidence comes at a crucial time when the demand for innovative healthcare solutions continues to rise. Daniel Nadler, CEO of OpenEvidence, highlighted the importance of their collaboration, stating, "OpenEvidence has become an accelerator for the dissemination of medical knowledge, with more than 40% of U.S. physicians actively using its point-of-care clinical decision support AI." Nadler emphasized that clinical trials are vital for patients with serious illnesses who have exhausted traditional treatment options. Through Open Vista, the goal is to connect physicians and patients with relevant clinical trials and cutting-edge therapies.

2. A Vision for the Future of Life Sciences

Veeva CEO Peter Gassner expressed enthusiasm for the partnership, stating, "We are very excited about our long-term partnership with OpenEvidence as we enter the AI chapter in life sciences." Gassner articulated a vision where the strengths of both companies could be combined to bridge the gap between life sciences companies producing life-saving medicines, patients, and the physicians who treat them. The Open Vista initiative aims to accelerate the development of new treatments, enhance patient participation in clinical trials, and facilitate better understanding and adoption of existing medications, ultimately leading to improved patient outcomes.

3. Anticipated Product Offerings

The first product offerings under the Open Vista partnership are expected to be launched in 2026. This timeline indicates a proactive approach to bringing innovative solutions to market, aligning with the increasing demand for technological advancements in healthcare.

4. About Veeva Systems

Veeva Systems is a leading provider of cloud-based software, data, and consulting services tailored for the life sciences industry. With a commitment to innovation and customer success, Veeva serves over 1,500 clients, including major biopharmaceutical companies and emerging biotechs. As a Public Benefit Corporation, Veeva balances the interests of various stakeholders, ensuring a holistic approach to its operations.

5. About OpenEvidence

OpenEvidence has rapidly become the foremost clinical decision support platform in the United States. Used by hundreds of thousands of verified healthcare professionals, the platform is instrumental in aiding high-stakes clinical decisions at the point of care. Currently utilized in more than 10,000 hospitals and medical centers, OpenEvidence is trusted by over 40% of U.S. physicians, consolidating its position as a pivotal resource in the medical community.

6. Conclusion

The partnership between Veeva Systems and OpenEvidence signals a transformative step in the life sciences industry, promoting the integration of AI in clinical practices. By enhancing patient access to clinical trials and improving treatment outcomes, Open Vista stands to redefine the landscape of healthcare and drug discovery. As both companies prepare to unveil their initial offerings in 2026, the industry eagerly anticipates the positive impact this collaboration will have on patients and healthcare providers alike.

Original press release